Mounjaro prior authorization: what to submit
Mounjaro's prior authorization turns on one fact: type 2 diabetes. Its label has no weight indication, so the request that succeeds documents diabetes, and the one that fails is written for weight.
What does a Mounjaro prior authorization need?
The type 2 diabetes diagnosis with a recent A1c; for a child, an age of 10 or older; for the cardiovascular indication, the high-risk history. No history of medullary thyroid carcinoma or MEN 2, and no second GLP-1. For weight, the plan will ask why Zepbound — the same molecule on a weight label — is not the prescription.
The use, and what it needs
Type 2 diabetes
Who the label covers: Adults and children 10 and older with type 2 diabetes; and, in adults with type 2 diabetes at high risk, reducing major cardiovascular events.
- The type 2 diabetes diagnosis with a recent A1c.
- For a child, the age: 10 and older is on the label, and on Medicaid, EPSDT covers what is medically necessary under 21 whatever the adult criteria say.
- For the cardiovascular indication, the history that makes the risk high, dated in the chart.
Indications read from FDA prescribing information for MOUNJARO, via DailyMed.
What every request carries
- No personal or family history of medullary thyroid carcinoma or MEN 2. It is the boxed warning, and every published GLP-1 criteria set asks; a blank answer is read as a fail.
- No second GLP-1 alongside it. Every state document on this site that addresses it says so, and a pharmacy claims history is how they check.
- Diet and physical activity as part of treatment. The label pairs every use with them, and criteria ask for it in writing.
- The indication written on the request in the label's words. A form that reads 'weight loss' invites a weight-loss exclusion even when the diagnosis behind it is something else.
How long the plan has
Set by regulation for each plan type, not by the plan. Which one you are on decides the clock.
Employer and marketplace plans
A standard prior authorization has to be decided within 15 days of the request, extendable once by 15; an urgent one within 72 hours. You have at least 180 days from a denial to appeal inside the plan, then four months from the final denial to ask for independent external review, unless the plan is grandfathered. 29 CFR 2560.503-1; 45 CFR 147.136
Medicare Part D, on its own or inside Medicare Advantage
72 hours for a standard coverage determination and 24 for an expedited one; for an exception the clock starts when the prescriber's supporting statement arrives. 60 days from the notice to ask the plan for a redetermination, longer if you show good cause. 42 CFR 423.568; 42 CFR 423.572; 42 CFR 423.582
Medicaid, fee-for-service or managed care
Federal Medicaid law requires an answer to a drug prior authorization within 24 hours, and a 72-hour emergency supply while it is pending. In a managed care plan you have 60 days from a denial to appeal to the plan, which must decide within 30 days, or 72 hours if it is urgent. On a decision the state makes itself, it may allow up to 90 days to ask for a fair hearing. Social Security Act §1927(d)(5); 42 CFR 438.402; 42 CFR 438.408; 42 CFR 431.221
Where your plan's own criteria are
Mounjaro prior authorization, answered
- Can Mounjaro be approved for weight loss?
- No — its label has no weight indication. A plan considering tirzepatide for weight considers Zepbound.
- Can a child be prescribed Mounjaro?
- Yes, from 10 years old, for type 2 diabetes; that is on the label. Zepbound is approved for adults only.